Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

Area of Science:

• Oncology
• Cardiology
• Immunology

Background:

• Immune-checkpoint inhibitors (ICIs) like anti-CTLA-4 and PD-1 agents offer significant antitumor responses in various cancers, including melanoma, NSCLC, and RCC.
• While improving survival, ICIs are associated with immune-mediated adverse events, including cardiotoxicity.
• Cardiotoxicity from ICIs, presenting as myocarditis or pericarditis, has been reported in individual cases.

Purpose of the Study:

• To report the largest case series to date on immune-related cardiotoxicity associated with ICI therapy.
• To describe the diagnostic findings, treatment strategies, and outcomes of patients experiencing cardiotoxicity.
• To emphasize the importance of awareness and monitoring for cardiac adverse events in patients receiving ICIs.

Main Methods:

• Retrospective analysis of eight cases of immune-related cardiotoxicity.
• Cases were identified across six clinical cancer centers with extensive ICI experience.
• Data collected included diagnostic findings, treatment interventions, and patient follow-up.

Main Results:

• A wide spectrum of cardiotoxic events was observed, including heart failure, cardiomyopathy, heart block, myocardial fibrosis, and myocarditis.
• Patients received various treatments, including corticosteroids, which were critical for management.
• The case series represents the most extensive compilation of ICI-induced cardiotoxicity to date.

Conclusions:

• Immune-related cardiotoxicity is a significant adverse event associated with ICI therapy.
• Vigilant monitoring, especially in patients with pre-existing cardiac conditions, is crucial.
• Prompt evaluation and appropriate treatment, including steroids, are essential for managing ICI-induced cardiotoxicity and ensuring patient safety.